Hanall Biopharma (009420) financial statements

+109.1%since 2013
FY2025 revenue
₩155.2B▲ +11.7%
FY2025 net income
−₩5.6B
FY2025 diluted EPS
−₩109.00
FY2025 free cash flow
−₩3.3B▼ −142.6%

Hanall Biopharma income statement

Hanall Biopharma income statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue155,185138,944134,910
Gross profit80,85873,30675,172
Operating income-9162302,211
Pretax income-6,180-1833,203
Net income-5,559-1,8053,509
Diluted earnings per share-109.00-36.0069.00

Hanall Biopharma balance sheet

Hanall Biopharma balance sheet
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents24,74316,38633,723
Total assets225,224212,881239,747
Total liabilities63,54344,52953,529
Total equity161,681168,351186,218
Long-term debt15,00000

Hanall Biopharma cash flow statement

Hanall Biopharma cash flow statement
KRW millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow-2,3409,36029,643
Capital expenditure-948-1,642-2,412
Free cash flow (derived)-3,2887,71827,231

Quarterly highlights

Quarterly highlights
KRW millionsQ2 FY2026Q1 FY2026Q4 FY2025Q3 FY2025
Period ended30 Jun 202631 Mar 202631 Dec 202530 Sep 2025
Revenue (derived)44,27640,03137,54940,804
Operating income (derived)5,598839-2,016349
Net income (derived)-19,229275-6,249299
Diluted earnings per share-378.005.00n/a6.00
Operating cash flow (derived)-6,6622,458-12,6767,341
Total assets240,514243,834225,224201,818

Hanall Biopharma major shareholders

Hanall Biopharma major shareholders
HolderShare of classSharesFiled
국민연금공단10.6%5,518,01930 June 2026

Hanall Biopharma DART filings

Hanall Biopharma DART filings
FiledFormType
13 August 2026Semiannual ReportHalf-year report
14 May 2026Quarterly ReportQuarterly report
28 April 2026Major Matters ReportCurrent report
17 March 2026Business ReportAnnual report
8 March 2026Major Matters ReportCurrent report
24 February 2026Major Matters ReportCurrent report
13 November 2025Quarterly ReportQuarterly report
28 October 2025Major Matters ReportCurrent report

Common questions

What was Hanall Biopharma's revenue in fiscal 2025?

Hanall Biopharma reported ₩155.2 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 11.7% from fiscal 2024.

What was Hanall Biopharma's net income in fiscal 2025?

Hanall Biopharma reported a net loss of ₩5.6 billion for fiscal 2025, the year ended 31 December 2025. Diluted earnings per share were −₩109.00.

What was Hanall Biopharma's free cash flow in fiscal 2025?

Hanall Biopharma had negative free cash flow of ₩3.3 billion in fiscal 2025. Operating cash flow was -₩2.3 billion and capital expenditure was ₩948 million.

What were Hanall Biopharma's total assets at the end of fiscal 2025?

Hanall Biopharma reported total assets of ₩225.2 billion at the end of fiscal 2025, the year ended 31 December 2025.

How much Hanall Biopharma history does each plan include?

Free covers the last 3 fiscal years of annual figures. Basic covers the last 10 fiscal years, annual and quarterly. Pro covers the full history, with first reported values and as of dates.